Current evidence for directed and supportive investigational therapies against COVID-19Review Published on 2020-04-302022-10-28 Journal: African Journal of Thoracic and Critical Care Medicine [Category] COVID-19, [키워드] benefit Chloroquine clinical trials control group Coronavirus disease 2019 Corticosteroids Course COVID-19 current drug effective Evidence Favipiravir Health Hydroxychloroquine Interpretation Intervention Investigational directed therapies limitation Lopinavir/ritonavir patients peer-reviewed randomised controlled randomised controlled trial Registered Remdesivir Safe selected small sample size supportive therapy the disease Therapies therapy Tocilizumab Treatment Trial trials [DOI] 10.7196/AJTCCM.2020.v26i2.072 PMC 바로가기 [Article Type] Review
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodiesArticle Published on 2020-04-162023-07-02 Journal: International journal of antimicrobial agents [Category] SARS, [키워드] Chloroquine COVID-19 Cytokine storm Hydroxychloroquine Tocilizumab [DOI] 10.1016/j.ijantimicag.2020.105982 PMC 바로가기 [Article Type] Article
Why tocilizumab could be an effective treatment for severe COVID-19?Commentary Published on 2020-04-142022-10-30 Journal: Journal of Translational Medicine [Category] COVID-19, SARS, [키워드] acute respiratory distress acute respiratory distress syndrome (ARDS) Admission alveolar Analysis ARDS Autopsy cause caused contribute COVID-19 COVID-19 patient died effective Gas exchange high mortality Host immune response ICU IL-6 IL-6 pathway IL-6 receptor impede Inflammatory cytokine storm inflammatory monocyte inflammatory storm intensive care monoclonal antibody Mortality New coronavirus pathogenic progressed public health Research Respiratory function returned SARS-CoV-2 severe complication severe COVID-19 severe COVID-19 patients Severe patient Spread suggested syndrome T cell target temperature therapeutic Tocilizumab Treatment [DOI] 10.1186/s12967-020-02339-3 PMC 바로가기 [Article Type] Commentary
Anti-IL6R role in treatment of COVID-19-related ARDSEditorial Published on 2020-04-142022-10-30 Journal: Journal of Translational Medicine [Category] Coronavirus, SARS, [키워드] ARDS COVID-19 IL-6 SARS-CoV-2 Tocilizumab Treatment [DOI] 10.1186/s12967-020-02333-9 PMC 바로가기 [Article Type] Editorial
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?Article Published on 2020-04-102023-07-01 Journal: Journal of autoimmunity [Category] SARS, [키워드] Coronavirus disease 2019 Cytokine release syndrome interleukin-6 Tocilizumab [DOI] 10.1016/j.jaut.2020.102452 PMC 바로가기 [Article Type] Article
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapyArticle Published on 2020-04-022023-06-15 Journal: Journal of autoimmunity [Category] MERS, SARS, [키워드] Antimalarials Baricitinib COVID-19 Rheumatic diseases SARS-CoV2 Tocilizumab [DOI] 10.1016/j.jaut.2020.102442 PMC 바로가기 [Article Type] Article
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortalityArticle Published on 2020-03-292023-06-18 Journal: International journal of antimicrobial agents [Category] MERS, SARS, [키워드] COVID-19 Cytokine release syndrome IL-6 IL-6R Tocilizumab [DOI] 10.1016/j.ijantimicag.2020.105954 PMC 바로가기 [Article Type] Article
Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitorsCommentary Published on 2020-03-262022-10-31 Journal: Immunotherapy [Category] COVID-19, MERS, SARS, [키워드] anti-CTLA-4 Anti-PD-1 anti-PD-L1 anticancer Cancer patients COVID-19 Immune checkpoint inhibitor Immune checkpoint inhibitors Immunotherapy SARS-CoV-2 Tocilizumab Treatment viral infection [DOI] 10.2217/imt-2020-0067 PMC 바로가기 [Article Type] Commentary
Rationale and design of the “Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled” trial (TOCIBRAS)"중등도에서 중증의 COVID-19 환자에 대한 토실리주맙: 공개 라벨 다기관 무작위 통제" 시험(TOCIBRAS)의 근거 및 설계Original Article Published on 2020-01-012022-08-13 Journal: Revista Brasileira de Terapia Intensiva [Category] 임상, [키워드] 7-point ordinal scale adjusted age and sex alleviate Analysis anti-inflammatory therapies Anti-inflammatory therapy applied approved Brazil C reactive protein Clinical outcome clinical outcomes clinical status combating consequence Coronavírus COVID-19 COVID-19 patient COVID-19 patients criteria D-dimer disease severity dissemination enrolment ethical committee Ethics ferritin IMPROVE inflammatory cascade inflammatory mediator Inflammatory response inhibiting institutional review board institutional review boards interleukin-6 International Lactate lactate dehydrogenase limit Local mediator moderate to severe multicentre National Odds ratio Open-label ordinal logistic regression Ordinal Scale outcome patients patients with COVID-19 patients with moderate primary endpoint Pro-inflammatory marker pro-inflammatory markers protocol Randomized Randomized controlled trial rationale required severe COVID-19 severity Standard of care Stratification Study protocol the disease The TOCIBRAS protocol TOCIBRAS Tocilizumab Tocilizumabe Trial trial testing variable [DOI] 10.5935/0103-507X.20200060 PMC 바로가기 [Article Type] Original Article
Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and TisiologySpecial Article Published on 2020-01-012022-10-29 Journal: Revista Brasileira de Terapia Intensiva [Category] COVID-19, [키워드] anticoagulation Bacterial Betacoronavirus Brasil Brazil Chloroquine clinical trials conducted Coronavirus infections/drug therapy Corticosteroids COVID-19 Diretrizes effective Effectiveness Evidence GRADE guideline guidelines hospitalized patients Infecções por coronavirus/tratamento farmacológico Infectious disease Influenza information Interpretation Intervention Medicine methodologist oseltamivir Patient pharmacological pharmacological treatment professional provided Pulmonology Rapid recommendation Result Safe SARS-CoV-2 Society systematic reviews Therapies therapy Tocilizumab treated Treatment use of hydroxychloroquine was performed [DOI] 10.5935/0103-507X.20200039 PMC 바로가기 [Article Type] Special Article